Best transplant surgeons: TOP 282 doctors

Prof. Baris Akin is a highly esteemed professor of surgery based in Istanbul, Turkey, with a specialization in kidney and pancreas transplantation. He received the 'Young Investigator Award' at the American Transplant Meeting in 2004 and has successfully conducted over 1200 kidney transplantations in Turkey. Prof. Akin has developed a new donor nephrectomy surgical technique and is certified as a transplant surgeon by the American Society of Transplant Surgeons.

2004 - 2006: Fellow, HBP Surgery and Liver Transplantation, Asan Medical Center

2006 - 2008: Fellow, Abdominal Transplantation, University of Cincinnati (Cincinnati, Ohio, USA)

2008 ~ 2009: Assistant Professor of Surgery, Abdominal Transplantation, University of Cincinnati (Cincinnati, Ohio, USA)

2007: Fellows Excellence in Research Award, Transplant Summit 2007

2015: The Korea Health & Medical Award 2015 (Organ Transplantation Center, General Hospital Division)

2006 -: Regular Member, American Society of Transplant Surgeon (ASTS)

2008 -: Regular Member, International Hepato-Pancreato-Biliary Association (IHPBA)

2008 -: Regular Member, International Liver Transplantation Society (ILTS)

2015 -: Member, Endoscopic and Laparoscopic Surgeons of Asia (ELSA)

2010: Training, Transplant Surgery, Queen Mary Hospital, University of Hong Kong

2008 - 2010: Fellow (accredited by American Society of Transplantation) , Transplant Surgery, University of Cincinnati medical Center (OH, USA)

Regular Member, International Pancreas and Islet Transplant Association (IPITA)

Regular Member, The Transplantation Society (TTS)

Regular Member, 미국이식학회는 American Society of Transplantation (AST), ASTS는미국이식외과의사협회 American Society of Transplant Surgeon

Education and Expertise

1996-2002 – Ankara University Faculty of Medicine – Medical Education

2003-2009 – Baskent University Faculty of Medicine, Department of General Surgery – Specialization Training

Experience

2009-2011 – Yüksekova State Hospital, Compulsory Service

2011-2012 – Van/Özalp, 6th Border Regiment, Military Service

2012-2018 – Baskent University Istanbul Health Application and Research Center Hospital

2018-2022 – Istanbul Aydın University Istanbul Health Practice and Research Center Hospital

Courses and Certificates

Selim Anorectal Diseases Course, Turkish Colon and Rectal Surgery Association, Istanbul, 17.12.2016 (National)

Training Program on Istanbul Protocol, Practitioner Training, Van, 06.11.2009-07.11.2009 (International)

Burn Course, Ankara Surgery Association, Başkent University, Ankara, 11.04.2009 (National)

Gazi Hernia Days, Hernia Course, Gazi University, Ankara, 18.10.2008-19.10.2008 (National)

Innovations in Breast Cancer Diagnosis and Treatment, Ankara Breast Diseases Association, Ankara, 22.03.

Biography

Dr. Mehdi Afrit is a Medical Oncologist who practices at Burjeel Specialty Hospital in Sharjah. He has over 11 years of experience caring for and managing cancer patients. He has extensive experience providing chemotherapy, hormonal therapy, immunotherapy, and targeted therapy to patients. He earned a Certificate of Medical Oncology from the Gustave Roussy Institute in Paris, France, where he received training in antitumor chemotherapy and cancer medical treatment. Additionally, he holds an international certificate in breast diseases. He also has a certificate in Good Clinical Practice from Trans Celerate Biopharma Inc. and a certificate in Clinical Trial Management: Good Clinical Practice from the Faculty of Pharmaceutical Medicine of the Royal College of Physicians. He previously worked for over five years as an Assistant Professor of Medical Oncology at Tunis’s Faculty of Medicine. He later practiced as a Consultant, Medical Oncologist for six years at Arianna’s hospital in Tunisia. He later worked for two years as a Specialist Medical Oncologist at Zulekha Hospital. He was also an investigator in three international clinical trials and holds clinical trial auditing and CRO certifications and a GCP Training Certificate from 2016. He is a member in good standing of the Emirates Oncology Society (EOS), the European Society of Medical Oncology (ESMO), and the American Society of Clinical Oncology (ASCO). His clinical expertise includes but is not limited to the following:

• Oncology care and treatment for chemotherapy, hormonal therapy, immune therapy, and target therapy
• Breast cancer
• Solid tumor diagnosis
• Digestive cancer
• Gynecological cancer
• Lung cancer
• Genitourinary cancer
• Sarcoma

Awards & Achievements

• Award from Himaya Foundations and University of Sharjah

Research & Publications

• Clinicopathological Features of Gastric Cancer in a Cohort of Gulf Council Countries' Patients: A Cross-Sectional Study of 96 Cases. Journal of Oncology Research Reviews & Reports Volume 2(2): 1-3.
• The Burden of Gynecologic Cancers in the UAE. Journal of Oncology Research Reviews & Reports Volume 2(4): 1-6.
• The Emirates Oncology Task Force Clinical Practice Guideline on Screening for SARS-CoV-2 in Asymptomatic Adult Cancer Patients Before Anti-Cancer Therapy. Journal of Oncology Research Reviews & Reports Volume 2(4): 1-6.
• The State of Cancer Care in the United Arab Emirates in 2020: Challenges and Recommendations, A report by the United Arab Emirates Oncology Task Force. Humaid Al-Shamsi, Humaa Darr, Ibrahim Abu-Gheida , Jawaher Ansari, Martine, Mehdi Afrit, Mohamad H Masri, Mohamed Abuhaleeqa. Gulf J Oncology 2020 Jan;1(32):71-87.
• Primary Bone Lymphoma: Tunisian Multicentric Retrospective Study About 32 Cases. Ben Ayed C, Laabidi S, Said N, Afrit M, Ben Ahmed S, Boussen H. Tunis Med. 2018 May;96(5):269-272.
• First Site of Recurrence After Breast Cancer Adjuvant Treatment in the Era of Multimodality Therapy: Which Imaging for Which Patient During Follow-up? Nesrine M, Mehdi B, Houda EB, Soumaya L, Mehdi A, Bechir Z, Hamouda B. Breast Dis. 2017 Nov 21

BRIEF SUMMARYOF WORK EXPERIENCE 

Including those I had transplanted during my fellowship at RUSH University in Chicago (n=86), I have performed a total of 705 liver transplants (%94 adult) both from living (%75) and cadaveric (%25) donors. And, additionally 340 kidney transplants which were mostly from living donors, too. Of these, 12 were combined liver and kidney transplantations either from cadaveric or living donors. Currently, I am the Director of Organ Transplant Program at GUVEN Hospital in Ankara. As of March 2018, here in GUVEN Hospital, we have performed 145 liver transplants (118 from living donors) with 1, 3 and 5 years patient survival of 91.2%, 86%and 83%, consecutively(ELTR data analysis). Since 1997, besides organ transplantation, I have also been operating on complicated hepato-pancreato-biliary patients

Current Workplaces: 

1 Izmir-Buca SSK Hospital 

2 Ankara Training and Research Hospital 

3 Başkent University 

4 Uludağ University 

5 Acıbadem University 

6 Florence Nightingale Hospital (current workplace) 

Education:

1989 Uludağ University Faculty of Medicine 

1984 Ankara Training and Research Hospital General Surgery Residency Training

International Articles: 

1. Uslu A. Bozkurt Y, Koç O, EmiroğluR. Çorumlu B. “Preoperative risk factors in patients with biliary obstruction”, Proc. 2 nd European Congress of Surgery. P179, Brussels,1992. 2. Emiroğlu R. Karakayah H, Haberal M. “Does the renal arterial anastomosis place affect the renal transplant patient outcome”, Proc. 25 th Annual Meeting of the American Society of Transplant Surgeons. P625,Chicago,1999 3. Karakayalı H, Moray G, Emiroğlu R. Akkoç R Köseoğlu F, Bilgin N, Haberal M “The results of interspousal kidney transplantation”, Proc.25 th Annual Meeting of the American Society of Transplant Surgeons. P625, Chicago, 1999 4.Emiroğlu R. Karakayalı H. Sevmiş Ş, Turan M. Bilgin N. Haberal M “Clinical identifıcation oftransplant antigens”, Proc. 36 th Congress of the ERA¬EDTA. P290, 1999. 5. Güz G, Emiroğlu R. Karakayalı H, Özdemir FN. Boy vat F. Haberal M. “An alternative method for native nefrectomy in patients with uncontrolled hypertension and/or proteinüria before transplantation”, Proc.36 th Congress of the ERA¬EDTA.P316, 1999 Prof. Remzi Emiroğlu, M.D. 6.Emiroğlu R. Köseoğlu F, Karakayalı H, Bilgin N. Haberal M. “Burn induced immunosuppression and ıt’s effects on graft survival, infection rates and apoptosis rates of “T” lymphocytes in rat model” Proc.Congress of Middle East and Fire Disaster Society, P52, Ankara, 2000. 7. Haberal M. Emiroğlu R.Mahmutoğlu M. Karakayalı H. Turan M, Erdal R. “Alport ‘s syndrome and renal transplantation” Proc.VII th Congress of Middle East Society for organ transplantation. P124, Beirut, 2000. 8. Gençoğlu EA, Aktaş A, Karakayalı H, Emiroğlu R. Niron EA, Haberal M. “Scintigraphic evaluation of graft and native liver fımction after heterotopic liver transplantation”, Proc. 7 th International Congress of the Middle East Society for Organ Transplantation. P141, Beirut, 2000 9. Haberal M, Karakayalı H, Emiroğlu R. Boyacıoğlu S, Arslan G, Bilgin N. “Heterotopic liver transplantation in adolescence” Proc. 7 th International Congress of the Middle East Society for Organ Transplantation. P138, Beirut, 2000 10. Haberal M, Emiroğlu R. Karakayalı H, Arslan G. Turan M. Bilgin N. “Living-donor transplants: Part of the answer to organ shortage”, Proc. 7 th International Congress of the Middle East Society for Organ Transplantation. P74, Beirut, 200011.Haberal M, Karakayalı H. Emiroğlu R. Köseoelu F, Akkoç H, Bilgin N. “Liver transplantation in an adolescent with allagille syndrome” Proc. 7 th International Congress of the Middle East Society for Organ Transplantation. P133, Beirut, 2000